CureToday: UC enrolling patients for glioblastoma trial

A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.

Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.

In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.

Read the article.

Read more about the trial.

For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.

Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.

Related Stories

Debug Query for this